Health
Results: 61-72 of 10100

Debiopharm Highlights Clinical Momentum Across DDR Portfolio at ESMO 2026, Advancing WEE1-Based Therapies in Ovarian and Uterine Cancers and Glioblastoma

Parse Biosciences Launches Evercode MAX, Enabling Researchers to Profile More Cells and Samples with Greater Flexibility

New Research from One Biosciences Shows Single-Cell Profiling Can Identify Which Ovarian Cancer Tumors are Predisposed to Chemotherapy Resistance






